What’s the current market cap for National Research stock?

National Research (NRC) has a market cap of $423m as of June 12, 2026.

What is the P/E ratio for National Research stock?

The price to earnings (P/E) ratio for National Research (NRC) stock is 48.79 as of June 12, 2026.

Does National Research stock pay dividends?

Yes, the National Research (NRC) stock pays dividends to shareholders. As of June 12, 2026, the dividend rate is $0.56 and the yield is 3.41%. National Research has a payout ratio of 130.97% on a trailing twelve-month basis.

When is the next National Research dividend payment date?

The next National Research (NRC) dividend payment is scheduled for July 10, 2026.

What is the beta indicator for National Research?

National Research (NRC) has a beta rating of 0.34. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy National Research stock | $NRC Share Price

13:30

15:10

16:45

18:25

20:00

About National Research

NRC Health operates as a humanized healthcare and support organization. Its platform includes Listen, Understand, and Improve. The group provides solutions for Patient, Consumer, Employee, and Market experiences. The group's commitment to Human Understanding helps healthcare systems get to know the patients, families, consumers, employees, and communities it on a human level.

Ticker

$NRC

Sector

Health

Primary listing

NASDAQ

Employees

357

Headquarters

Lincoln, United States

Website

www.nrchealth.com

NRC Metrics

BasicAdvanced

$423m

48.79

$0.39

0.34

$0.56

3.41%

Bulls say / Bears say

Total Recurring Contract Value reached a record USD 152.0 million as of March 4, 2026, up 6% sequentially and 13% year-over-year, highlighting a strong contract pipeline that should drive future revenue growth.

NRC Health anticipates revenue, operating margin, and operating cash flow will rise in 2026, supported by growth in TRCV and a lower expense run rate, reflecting management’s confidence in stronger efficiency.

The company changed its corporate name to NRC Health on April 15, 2026, strengthening its brand alignment with its human-focused healthcare solutions and potentially improving market recognition.

National Research Corp’s FY2025 revenue fell 4% year-over-year to USD 137.4 million, signaling continued top-line pressure after several years of contraction.

Operating income dropped 36% year-over-year to USD 22.6 million in FY2025, reducing the operating margin to 16% and pointing to ongoing margin challenges from increased expenses.

Cash flow from operating activities declined 24% year-over-year to USD 26.5 million in FY2025, raising doubts about the company’s ability to generate cash under its current business model.

Data summarised monthly by Lightyear AI. Last updated on 20 May 2026.

NRC Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $NRC

Capital at risk

Market open

Upcoming events